Health

FDA clears asundexian to cut repeat stroke risk

69 views

The U.S. Food and Drug Administration approved asundexian, sold as Sunharbo, on November 9. The drug is cleared to reduce the risk of stroke in adults who have had a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

That group is large. Non-cardioembolic strokes are the most common kind, and they are not caused by a clot travelling from the heart, so the usual blood thinners do not fit every patient.

Why the target matters

Asundexian blocks factor XIa, a protein in the clotting cascade. Medicines aimed at this step are designed to quiet the clotting that causes stroke while leaving enough clotting to stop bleeding.

That trade-off is the reason the class attracts attention. Older anticoagulants cut stroke risk but raise the chance of serious bleeds, and doctors often leave patients untreated when the bleeding risk looks high. A drug with a narrower effect could bring those patients into treatment.

The label and the limits

The approval covers secondary prevention, meaning patients who have already had an event. It does not cover the general population, and it does not replace the standard work of finding the cause of a stroke.

Regulators cleared the drug on the strength of its trial programme. As with any new blood agent, the label will carry bleeding warnings, and patients on other anticoagulants or antiplatelet drugs will need review before switching.

A busy approval year

Asundexian is number 48 on the agency's list of new molecular entities cleared in 2026. The list includes orforglipron for obesity, insulin icodec for type 2 diabetes and difamilast for atopic dermatitis.

Earlier in the autumn the agency approved bepirovirsen, sold as Hibsago, for chronic hepatitis B in certain adults without cirrhosis, used with existing antiviral therapy. It also cleared pritelivir for herpes skin lesions and a long-acting injectable form of olanzapine for schizophrenia.

For stroke patients, the practical effect starts when hospitals add the drug to formularies. Clinicians will watch real-world bleeding rates closely in the first year, because trial populations rarely match the patients seen in ordinary wards.

Source: U.S. Food and Drug Administration